Ellery Mangas

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Sound Pharmaceuticals Inc. manufactures biopharmaceutical products. It focuses on developing drug treatments for sensori-neural hearing loss. The company was founded by Eric Lynch, Joseph Ashley, Glenn H. Kawasaki and Jonathan Kil in 2001 and is headquartered in Seattle, WA.

Invectys, Inc. is a biopharmaceutical company that focuses on developing immunotherapy treatments for cancer. The private company is based in Houston, TX. Invectys was founded in 2010 and Praveen Tyle has been the CEO of the company since 2021.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Eyebiotech Ltd. is a British clinical stage ophthalmology company that treats patients with sight-threatening diseases. The company is based in London, UK. Eyebiotech was founded in 2021 by David R. Guyer and Anthony P. Adamis. David R. Guyer has been the CEO since 2021.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA.

Scioderm, Inc. engages in the development of innovative therapies for areas of high unmet need, including orphan products. The company was founded by Robert Ryan and Robert John Coull in 2012 and is headquartered in Durham, NC.

Carter BloodCare engages in the provision of blood components and transfusion services for North, Central and East Texas. It offers collection, testing, and distribution of blood on a local level. It also provides technical support services and educational programs to employees of area healthcare organizations. The company was founded on January 1, 1998 and is headquartered in Bedford, TX.

Simon-Kucher & Partners GmbH provides strategy, marketing and pricing services. It offers consulting services in the areas of setting and managing prices, strategic development, product and market strategy, marketing leadership, and sales execution. The firm has offices in Amsterdam, Bonn, Boston, Brussels, Cologne, Frankfurt, London, Luxembourg, Barcelona, Madrid, Milan, Moscow, Munich, New York, Paris, San Francisco, Tokyo, Vienna, Warsaw, Beijing, Singapore, Sydney and Zurich. The company was founded by Hermann Simon, Eckhard Kucher and Karl-Heinz Sebastian in 1985 and is headquartered in Bonn, Germany.

Part of W2 Group, Inc., Racepoint Global, Inc. is an independent communications agency that helps brands define their authentic story and builds channel-agnostic communication strategies to engage their target audience. Racepoint Global is headquartered in Boston, MA, with offices in San Francisco, Raleigh, and Washington DC, and its European headquarters in London. The agency specializes in driving conversations that matter for innovative brands, whether an enterprise brand or emerging category disruptor, to own the conversations and coverage that matters. The company's mission is to help clients navigate and succeed in the new communications landscape by shaping the conversations that matter, establishing competitive differentiation, and driving business impact. The company was founded by Marijean Lauzier, Vernon Lawrence Weber, and Larry Weber has been the CEO of the company since 2004.

Oxford Global Resources LLC provides information technology, engineering, regulatory and compliance consultants. It recruits functional and technical consultants in the areas of project management and business analysis, ERP, BI, CRM, SCM, database administration, application development, information security, and IT infrastructure. The company was founded in 1984 and is headquartered in Beverly, MA.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA.

Interius BioTherapeutics, Inc. is a biopharmaceutical company that targets cancer. The company was founded by Saar Gill and is headquartered in Philadelphia, PA.

viTToria Biotherapeutics, Inc. is a gene-edited cell therapeutics company based in Philadelphia, PA. The company is developing novel CAR-T cell therapies using their proprietary Senza5 platform, which maximizes stemness, durability, and target cell cytotoxicity. The technology is exclusively licensed from the University of Pennsylvania and has pipeline applications in oncology and autoimmune diseases. The company was founded by Bruce A. Peacock and Nicholas Siciliano, with Nicholas Siciliano serving as CEO since incorporation.

Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts.

Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ.

Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Imagen Biotech, Inc. develops therapeutics for sight-threatening diseases. The firm specializes in personalized chemotherapy, medicine, high content screening, cell biology and contract research. The company was founded by David R. Guyer and Matthew Feinsod in 2011 and is headquartered in New York, NY.

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

Intergalactic Therapeutics, Inc. is a gene therapy company based in Baltimore, MD. The company is revolutionizing gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal c3dna molecules. The company uses a customized approach to focal therapeutic delivery using its lead delivery technology, the comet pulsed electric field system, and a proprietary cell-free manufacturing process invented to make gene therapy safer and more accessible for patients. With programs in ophthalmology, oncology, respiratory diseases, and expansion areas including CNS, renal, and musculoskeletal, Intergalactic Therapeutics is dedicated to transforming genetic medicine. The company was founded by Michael D. Ehlers, and Theresa G. H. Heah has been the CEO of the company since 2023.